(Press-News.org) MIAMI, FLORIDA (EMBARGOED UNTIL JAN. 4, 2024, at 10 AM EST) – Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes – and hope – to patients worldwide.
But treatment breakthroughs such as the immunotherapy drug teclistamab can lead to potentially lethal side effects, including cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS).
These potential side effects have necessitated giving immunotherapy drugs in the hospital setting, where patients remain for five to seven days and receive other drugs as needed to quell any immunotherapy complications.
Now, however, new research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine indicates that providing prophylactic treatment before immunotherapy can significantly reduce the rate of CRS in multiple myeloma patients.
The study, which appears Jan. 4, 2024, in Blood Cancer Discovery, a journal of the American Association for Cancer Research, could eliminate the need to administer teclistamab and other immunotherapies in hospitals, thereby broadening access to countless more cancer patients.
“In an ideal world, you could pre-medicate patients against CRS and treat them in an outpatient setting,” explained C. Ola Landgren, M.D., chief of the Division of Myeloma at Sylvester and co-corresponding study author. “As a result, there is huge interest in this possibility worldwide.”
T-Cell Engagers
Teclistamab and similar immunotherapies are known as bispecific T-cell engagers – drugs that bind targets on both tumor cells and T-cells, with the goal of getting T-cells to attack and ultimately shrink tumors.
In a key clinical study published in the New England Journal of Medicine, teclistamab produced an overall response rate of 63% in multiple myeloma patients whose tumors had failed to respond to multiple previous therapies or had become resistant to them. The drug received FDA approval for use with these patients in 2022, followed by two other bispecific T-cell engagers.
“These immunotherapy drugs work by revving the immune system’s response against the tumor,” Landgren explained. “But the process can lead to an overactive immune response, the hallmark of CRS.”
Physicians often treat CRS with drugs that counteract the cytokine release that causes T-cells to go into overdrive. Tocilizumab, for example, has been used for years to treat CRS from immunotherapies.
That’s why patients receiving teclistamab typically need a multi-day hospital stay for monitoring during therapy, prompting some patients to forgo the therapy. “It’s a big barrier for many patients,” he said.
Landgren and colleagues were inspired to conduct their research after reviewing preliminary data from a 2022 study on multiple myeloma patients treated prophylactically with tocilizumab. That study showed the approach eased CRS in patients receiving a different bispecific T-cell engager than teclistamab.
In their study, which included 31 multiple myeloma patients, Landgren and collaborators reported that only 13% developed CRS after prophylactic treatment with tocilizumab. The results were in stark contrast to the 72% observed in an earlier study treating patients for CRS as symptoms arose. Additionally, patients in this newer study had less severe CRS and lower rates of its recurrence.
This preventive approach also appeared to ease ICANS, a second, less common side effect causing neurotoxicity.
“Prophylactic treatment with tocilizumab is now standard of care at Sylvester for multiple myeloma patients receiving T-cell engagers,” said Andrew Kowalski, PharmD, a hematology/oncology clinical pharmacist at Sylvester and the study’s lead author. “We are ahead of the curve.”
Similarly, patients receiving CAR-T cell immunotherapy also seem to benefit from prophylactic CRS treatment, according to the study’s authors.
Future plans
Some questions about prophylactic treatment remain. Does it reduce the effectiveness of immunotherapy drugs? So far, the answer appears to be no, according to both Kowalski and Landgren. Can it benefit patients with other blood cancers? Yes!
“This preventive approach has the potential to be expanded into leukemias and lymphomas as well,” Kowalski said.
The Sylvester researchers are preparing for future changes in treatment settings. They are quietly readying an outpatient service to deliver teclistamab and other emerging immunotherapies, anticipating that U.S. regulators may lift the hospital-stay requirement.
Landgren likened this evolution to a previous one with the cancer drug rituximab, which initially required monitoring in an intensive care unit but now can be given outside the hospital.
“The field of myeloma is probably one of the biggest examples of successful drug development in modern times,” he said. “We are going with full steam into an era of immunotherapy.”
# # #
Article Title: “Emerging Strategies for the Prevention of Immune Toxicities Associated with T-cell-Engaging Cancer Therapies”
Authors: In addition to Landgren and Kowalski, other Sylvester authors were Jill Lykon, Benjamin Diamond, David G. Coffey, Marcella Kaddoura, Francesco Maura, James E. Hoffman and Dickran Kazandjian.
Funding: This research was funded by the Sylvester Comprehensive Cancer Center NCI Core Grant (P30 CA 240139) and the Riney Family Multiple Myeloma Research Program Fund.
Disclosures: The authors reported competing interests that are noted in the study.
Follow @SylvesterCancer on X for the latest in cancer research and care.
# # #
END
A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection. They also found a higher proportion of individuals with acute symptoms rebound and test-positivity than previously reported.
The study appears Jan. 4, 2024, in the Journal of Medical Virology.
Paxlovid treatment for acute COVID-19 has been shown to be effective for high-risk unvaccinated individuals. But the effect of the treatment on long COVID risk, including whether it protects vaccinated people from getting long COVID, has been less clear.
The ...
● KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype.
● The molecule has demonstrated strong preclinical activity. Insilico Medicine presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.
● This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
FLORENCE, Italy and NEW YORK: The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, ...
INDIANAPOLIS – A significant obstacle to improving care and outcomes for intensive care unit (ICU) patients is the unexpected nature of becoming seriously ill. Which groups of patients are likely to become severely ill and will they survive their ICU stay?
In a first step in creating infrastructure for further studies to identify and follow cohorts of patients who may become critically ill, researchers including Sikandar Khan, D.O, M.S., of Regenstrief Institute and Indiana University School of Medicine, have developed and conducted ...
Firms worldwide are increasingly adopting electronic voting, enabling shareholders to cast their votes online, instead of attending shareholder meetings in-person. Shareholders can enjoy superior accessibility to the meetings with electronic voting, compared to those with traditional and in-person setups. Despite the emerging popularity of electronic voting in recent years, however, there is limited evidence of its impact on governance.
To address this gap in research, Associate Professor Wonsuk Ha from the School of Business Administration, Chung-Ang University, along ...
WASHINGTON—A new Journal of the Endocrine Society study among women attending a fertility center found that those with more stress before pregnancy had higher blood sugar levels during pregnancy, which is a sign of weaker cardiovascular health.
People’s stress levels have continued to rise over the years, particularly in the last few years due to the COVID-19 pandemic, putting them at risk for serious health issues such as heart disease. Research shows women may experience more stress than men, especially those going through infertility. Maintaining a healthy pregnancy ...
Stress during pregnancy is known to influence health outcomes, but a new study from Mass General Brigham researchers suggests that stress levels before pregnancy are also important to evaluate. Investigators at Massachusetts General Hospital and Brigham and Women’s Hospital analyzed the link between self-reported stress immediately before conception among women seeking fertility care and blood glucose levels, a marker of heart health. The team found that maternal stress during preconception ...
New York, NY [January 4, 2023]—In a milestone study, researchers from the Icahn School of Medicine at Mount Sinai have harnessed the power of artificial intelligence (AI) to enhance the assessment of the heart’s right ventricle, which sends blood to the lungs.
Conducted by a team using AI-enabled electrocardiogram (AI-ECG) analysis, the research demonstrates that electrocardiograms can effectively predict right-side heart issues, offering a simpler alternative to complex imaging technologies and potentially enhancing patient outcomes.
The findings were described in the December 29 online ...
SPOKANE, Wash. – Even small differences in the availability of urban green and blue spaces may be associated with better mental and physical health in older adults, according to a Washington State University study.
The study’s findings showed that having just 10% more forest space in a person’s residential ZIP code was associated with reduced serious psychological distress, which covers mental health problems that require treatment and interfere with people’s social lives, work or school. Similarly, a 10% increase in green space, tree cover, water bodies ...
100 years of Science Changing Life: Scripps Research celebrates a century of transforming human health
LA JOLLA, CA—Scripps Research, a nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation, will celebrate its 100-year history throughout 2024. This significant milestone marks a century of seminal discoveries in immunology, infectious diseases (such as COVID-19, flu, HIV), neuroscience, heart disease, cancer, and more. The institute has also made strides in groundbreaking chemistry advances, drug development and educational ...
Chicago, January 4, 2024 — The JAMA Network today announces a new class of seven academic physicians and nurses selected for a new program to provide junior faculty and current research fellows opportunities to learn about biomedical journals and scientific publication. This inaugural group of fellows will spend six months immersed as part of the JAMA editorial team to obtain direct exposure to the editorial review process and enhance their skills in scientific communication.
Fellows will be assigned to a current JAMA editor for mentorship, attend manuscript meetings, participate in discussions about research design, data validity, potential clinical importance, and conduct ...
